Lipid-lowering therapy today: treating the high-risk cardiovascular patient

The Journal of Cardiovascular Nursing
Kathleen Berra

Abstract

Diseases of the heart and vascular systems are the leading cause of death in the United States and worldwide. High-risk patients have been the focus of lipid-lowering trials and treatment guidelines, which recognize that more intensive reduction of low-density lipoprotein cholesterol is appropriate for a redefined, broader high-risk population. Lifestyle modifications and lipid-lowering drug therapy form the foundation of primary- and secondary-prevention programs for patients at moderate to very high risk. Evidence shows that despite the availability of effective agents, such as HMG CoA reductase inhibitors (statins), many patients still do not achieve low-density lipoprotein cholesterol goals. Nurse-centered case management programs that support early and continued adherence with lifestyle and medical therapies have been consistently successful at improving the rates of achieving lipid goals in high-risk patients.

References

May 26, 1998·JAMA : the Journal of the American Medical Association·J AvornJ LeLorier
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Jul 26, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Marc Evans, Alan Rees
Sep 21, 2002·Lancet·Duncan M Geddes
Sep 24, 2002·The Annals of Pharmacotherapy·Stephen J Shalansky, Adrian R Levy
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Apr 30, 2004·Clinical Pharmacology and Therapeutics·Dennis W SchneckAli Raza
Jun 18, 2004·Current Medical Research and Opinion·Teddy KosoglouEnrico P Veltri
Aug 25, 2004·Current Medical Research and Opinion·Teddy KosoglouDavid L Cutler
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Dec 15, 2005·The Annals of Pharmacotherapy·Sarah J SchwiesowKelly R Ragucci
Dec 22, 2005·American Heart Journal·Sonali P KulkarniEric D Peterson
Sep 9, 2006·Journal of the American Academy of Nurse Practitioners·Kathryn A Paez, Jerilyn K Allen
Nov 28, 2006·The American Journal of Cardiology·William L HaskellJeff Myll
Feb 21, 2007·Circulation·Lori MoscaUNKNOWN American College of Nurse Practitioners
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
May 1, 2007·Journal of the American College of Cardiology·Michael H Davidson, Jennifer G Robinson

❮ Previous
Next ❯

Citations

Aug 27, 2009·The Journal of Cardiovascular Nursing·Linda GaravaliaCarole Decker
Oct 28, 2019·International Journal of Environmental Research and Public Health·Kenny Mendoza-HerreraSimón Barquera

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.